Do analysts prefer XGN or PRPO?

Exagen presently has a consensus target price of $9.63, indicating a potential upside of 36.91%. Given Exagen's stronger consensus rating and higher probable upside, equities analysts plainly believe Exagen is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, XGN or PRPO?

Precipio has lower revenue, but higher earnings than Exagen. Precipio is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 2.56 -$19.95M -$0.81 N/A Precipio $24.05M 2.03 -$360K -$0.64 N/A

Is XGN or PRPO more profitable?

Precipio has a net margin of -4.47% compared to Exagen's net margin of -26.61%. Precipio's return on equity of -8.49% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% Precipio -4.47% -8.49% -5.75%

Do analysts rate PRPO or LFMD?

LifeMD has a consensus target price of $7.57, suggesting a potential upside of 148.24%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has higher valuation & earnings, PRPO or LFMD?

LifeMD has higher revenue and earnings than Precipio. LifeMD is trading at a lower price-to-earnings ratio than Precipio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precipio $24.05M 2.03 -$360K -$0.64 N/A LifeMD $194.05M 0.76 $14.35M -$0.05 N/A

Is PRPO or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to Precipio's net margin of -4.47%. Precipio's return on equity of -8.49% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets Precipio -4.47% -8.49% -5.75% LifeMD 0.10% -168.23% -31.27%

Do analysts prefer PRPO or JYNT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Joint 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, PRPO or JYNT?

Joint has higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precipio $24.05M 2.03 -$360K -$0.64 N/A Joint $54.90M 2.02 $2.91M $0.27 29.07

Is PRPO or JYNT more profitable?

Joint has a net margin of 6.49% compared to Precipio's net margin of -4.47%. Joint's return on equity of 12.02% beat Precipio's return on equity. Company Net Margins Return on Equity Return on Assets Precipio -4.47% -8.49% -5.75% Joint 6.49% 12.02% 3.47%

Do analysts prefer PRPO or PARK?

Park Dental Partners has a consensus price target of $28.50, suggesting a potential upside of 38.42%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts clearly believe Park Dental Partners is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Park Dental Partners 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, PRPO or PARK?

Precipio is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precipio $24.05M 2.03 -$360K -$0.64 N/A Park Dental Partners $244.49M 0.40 -$360K $1.05 19.61

Do analysts prefer PRPO or ACH?

Accendra Health has a consensus price target of $1.50, suggesting a potential upside of 40.19%. Given Accendra Health's stronger consensus rating and higher probable upside, analysts clearly believe Accendra Health is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Accendra Health 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Precipio (PRPO) Competitors

$27.32 +0.41 (+1.52%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$27.69 +0.37 (+1.35%)

As of 09/11/2026 07:30 PM Eastern

Compare

PRPO vs. XGN, LFMD, JYNT, PARK, and ACH

Should you buy Precipio stock or one of its competitors? Precipio's main competitors and comparable companies include Exagen (XGN), LifeMD (LFMD), Joint (JYNT), Park Dental Partners (PARK), and Accendra Health (ACH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Precipio compare to Exagen?

Exagen (NASDAQ:XGN) and Precipio (NASDAQ:PRPO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Precipio has a net margin of -4.47% compared to Exagen's net margin of -26.61%. Precipio's return on equity of -8.49% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Precipio	-4.47%	-8.49%	-5.75%

Exagen has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market. Comparatively, Precipio has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

In the previous week, Exagen had 4 more articles in the media than Precipio. MarketBeat recorded 5 mentions for Exagen and 1 mentions for Precipio. Precipio's average media sentiment score of 1.87 beat Exagen's score of 1.18 indicating that Precipio is being referred to more favorably in the news media.

Company	Overall Sentiment
Exagen	Positive
Precipio	Very Positive

Precipio has lower revenue, but higher earnings than Exagen. Precipio is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	2.56	-$19.95M	-$0.81	N/A
Precipio	$24.05M	2.03	-$360K	-$0.64	N/A

Exagen presently has a consensus target price of $9.63, indicating a potential upside of 36.91%. Given Exagen's stronger consensus rating and higher probable upside, equities analysts plainly believe Exagen is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

75.3% of Exagen shares are owned by institutional investors. Comparatively, 10.5% of Precipio shares are owned by institutional investors. 10.4% of Exagen shares are owned by company insiders. Comparatively, 16.6% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Exagen beats Precipio on 10 of the 17 factors compared between the two stocks.

How does Precipio compare to LifeMD?

Precipio (NASDAQ:PRPO) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

LifeMD has a consensus target price of $7.57, suggesting a potential upside of 148.24%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, LifeMD had 4 more articles in the media than Precipio. MarketBeat recorded 5 mentions for LifeMD and 1 mentions for Precipio. Precipio's average media sentiment score of 1.87 beat LifeMD's score of 0.90 indicating that Precipio is being referred to more favorably in the media.

Company	Overall Sentiment
Precipio	Very Positive
LifeMD	Positive

LifeMD has higher revenue and earnings than Precipio. LifeMD is trading at a lower price-to-earnings ratio than Precipio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05M	2.03	-$360K	-$0.64	N/A
LifeMD	$194.05M	0.76	$14.35M	-$0.05	N/A

Precipio has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, LifeMD has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

LifeMD has a net margin of 0.10% compared to Precipio's net margin of -4.47%. Precipio's return on equity of -8.49% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
LifeMD	0.10%	-168.23%	-31.27%

10.5% of Precipio shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 16.6% of Precipio shares are owned by insiders. Comparatively, 17.2% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

LifeMD beats Precipio on 11 of the 16 factors compared between the two stocks.

How does Precipio compare to Joint?

Precipio (NASDAQ:PRPO) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Precipio and Precipio both had 1 articles in the media. Precipio's average media sentiment score of 1.87 beat Joint's score of 1.81 indicating that Precipio is being referred to more favorably in the media.

Company	Overall Sentiment
Precipio	Very Positive
Joint	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Joint	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Joint has higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05M	2.03	-$360K	-$0.64	N/A
Joint	$54.90M	2.02	$2.91M	$0.27	29.07

Joint has a net margin of 6.49% compared to Precipio's net margin of -4.47%. Joint's return on equity of 12.02% beat Precipio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
Joint	6.49%	12.02%	3.47%

10.5% of Precipio shares are held by institutional investors. Comparatively, 76.9% of Joint shares are held by institutional investors. 16.6% of Precipio shares are held by company insiders. Comparatively, 30.2% of Joint shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Precipio has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Joint has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Summary

Joint beats Precipio on 10 of the 13 factors compared between the two stocks.

How does Precipio compare to Park Dental Partners?

Precipio (NASDAQ:PRPO) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

10.5% of Precipio shares are held by institutional investors. 16.6% of Precipio shares are held by company insiders. Comparatively, 10.6% of Park Dental Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Precipio and Precipio both had 1 articles in the media. Park Dental Partners' average media sentiment score of 1.89 beat Precipio's score of 1.87 indicating that Park Dental Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Precipio	Very Positive
Park Dental Partners	Very Positive

Park Dental Partners has a consensus price target of $28.50, suggesting a potential upside of 38.42%. Given Park Dental Partners' stronger consensus rating and higher probable upside, analysts clearly believe Park Dental Partners is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Precipio is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05M	2.03	-$360K	-$0.64	N/A
Park Dental Partners	$244.49M	0.40	-$360K	$1.05	19.61

Park Dental Partners has a net margin of 0.00% compared to Precipio's net margin of -4.47%. Park Dental Partners' return on equity of 0.00% beat Precipio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
Park Dental Partners	N/A	N/A	N/A

Summary

Park Dental Partners beats Precipio on 11 of the 14 factors compared between the two stocks.

How does Precipio compare to Accendra Health?

Precipio (NASDAQ:PRPO) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Precipio has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

10.5% of Precipio shares are held by institutional investors. 16.6% of Precipio shares are held by insiders. Comparatively, 2.3% of Accendra Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Precipio has a net margin of -4.47% compared to Accendra Health's net margin of -11.41%. Accendra Health's return on equity of -4.02% beat Precipio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
Accendra Health	-11.41%	-4.02%	0.70%

Precipio has higher earnings, but lower revenue than Accendra Health. Precipio is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05M	2.03	-$360K	-$0.64	N/A
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A

Accendra Health has a consensus price target of $1.50, suggesting a potential upside of 40.19%. Given Accendra Health's stronger consensus rating and higher probable upside, analysts clearly believe Accendra Health is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Precipio had 1 more articles in the media than Accendra Health. MarketBeat recorded 1 mentions for Precipio and 0 mentions for Accendra Health. Precipio's average media sentiment score of 1.87 beat Accendra Health's score of 0.00 indicating that Precipio is being referred to more favorably in the media.

Company	Overall Sentiment
Precipio	Very Positive
Accendra Health	Neutral

Summary

Precipio beats Accendra Health on 8 of the 15 factors compared between the two stocks.

Get Precipio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRPO vs. The Competition

Export

Metric	Precipio	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$48.91M	$9.84B	$7.16B	$12.85B
Dividend Yield	N/A	2.61%	2.57%	11.17%
P/E Ratio	-42.69	33.53	274.94	25.36
Price / Sales	2.03	4.89	686.01	116.83
Price / Cash	34.39	125.15	76.65	51.52
Price / Book	3.29	5.29	10.33	6.20
Net Income	-$360K	$313.25M	$3.50B	$358.50M
7 Day Performance	-0.29%	-1.26%	-3.32%	-2.35%
1 Month Performance	17.71%	-1.53%	-0.53%	-3.23%
1 Year Performance	40.10%	58.44%	23.51%	8.79%

Precipio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRPO Precipio	0.4715 of 5 stars	$27.32 +1.5%	N/A	+40.1%	$48.91M	$24.05M	N/A	60	Positive News
XGN Exagen	4.3138 of 5 stars	$7.38 +1.0%	$9.63 +30.5%	-27.8%	$178.90M	$71.12M	N/A	220	News Coverage Positive News Analyst Forecast
LFMD LifeMD	2.4614 of 5 stars	$2.94 -5.0%	$7.57 +158.0%	-47.4%	$141.47M	$191.59M	N/A	230	Positive News Analyst Forecast
JYNT Joint	2.7784 of 5 stars	$8.09 -1.2%	N/A	-22.0%	$114.53M	$54.90M	30.00	320
PARK Park Dental Partners	4.6129 of 5 stars	$20.41 +1.1%	$28.50 +39.7%	N/A	$97.13M	$244.49M	19.43	1,212	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRPO) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precipio (PRPO) Competitors